アルフェンタニル

使用用途

• As a premed
• As a constant rate infusion for pain
• As an analgesic supplement to anesthesia
• For intra-operative analgesia in patients with intracranial disease
• Intraoperative analgesia
• Intraoperative analgesia
• Intraoperative analgesia
• Intraoperative analgesia

投与方法

考えられる副作用

• Dose-related respiratory depression
• Bradycardia
• CNS depression
• Dose-related skeletal muscle rigidity
• Asystole (rare)
• Hypercarbia (rare)
• Hypersensitivity reactions (rare)

注意事項と禁忌

• Patients hypersensitive to opioids
• > **Critical Warning:** Because of the drug's potency and potential for significant adverse effects, it should **only** be used in situations where patient vital signs can be continuously monitored. * **Dose Adjustments:** Initial dosage reduction may be required in geriatric or debilitated patients, particularly those with diminished cardiopulmonary function or liver disease. * **Muscle Rigidity:** Dose-related skeletal muscle rigidity is not uncommon; neuromuscular blockers are routinely used in conjunction. * **Laboratory Artifacts:** May increase plasma levels of amylase or lipase secondary to increased biliary tract pressure. Values may be unreliable for 24 hours post-administration.

薬物相互作用

• CYP3A4 Inhibitors (erythromycin, cimetidine, ketoconazole, itraconazole, fluconazole, diltiazem): May increase the half-life and decrease the clearance of alfentanil leading to prolonged effect and an increased risk of respiratory depression
• Beta-blockers: May produce bradycardia or hypotension if used concurrently with alfentanil
• Other anesthetic agents: May produce bradycardia or hypotension; respiratory or CNS depression may be exacerbated
• Inhaled anaesthetics: Reduces the dose requirements of concurrently administered anaesthetics by at least 50%
• Monoamine oxidase inhibitors (MAOIs): Risk of serotonin toxicity

よくある質問